Leerink Partnrs Brokers Lift Earnings Estimates for ACAD

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities research analysts at Leerink Partnrs lifted their Q2 2025 earnings estimates for ACADIA Pharmaceuticals in a research note issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will earn $0.21 per share for the quarter, up from their previous estimate of $0.17. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals’ Q4 2025 earnings at $0.17 EPS, FY2026 earnings at $0.65 EPS, FY2027 earnings at $1.05 EPS and FY2028 earnings at $1.75 EPS.

A number of other analysts have also issued reports on ACAD. Guggenheim lowered ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $23.00 to $20.00 in a research note on Friday, January 3rd. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Cantor Fitzgerald restated an “overweight” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They set a “hold” rating and a $22.00 price target on the stock. Finally, StockNews.com upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 8th. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $23.93.

ACADIA Pharmaceuticals Stock Down 2.8 %

Shares of ACADIA Pharmaceuticals stock opened at $14.57 on Tuesday. ACADIA Pharmaceuticals has a fifty-two week low of $13.40 and a fifty-two week high of $20.68. The business’s fifty day moving average is $17.32 and its two-hundred day moving average is $16.93. The firm has a market cap of $2.43 billion, a PE ratio of 18.68 and a beta of 0.54.

Institutional Trading of ACADIA Pharmaceuticals

Large investors have recently modified their holdings of the business. State Street Corp boosted its holdings in ACADIA Pharmaceuticals by 3.0% in the third quarter. State Street Corp now owns 5,973,874 shares of the biopharmaceutical company’s stock valued at $91,878,000 after purchasing an additional 173,084 shares during the last quarter. Barclays PLC boosted its stake in shares of ACADIA Pharmaceuticals by 126.2% during the 3rd quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company’s stock valued at $4,269,000 after buying an additional 154,854 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of ACADIA Pharmaceuticals by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,875,540 shares of the biopharmaceutical company’s stock valued at $44,234,000 after buying an additional 30,826 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of ACADIA Pharmaceuticals by 67.8% during the third quarter. Principal Financial Group Inc. now owns 129,551 shares of the biopharmaceutical company’s stock worth $1,992,000 after buying an additional 52,340 shares in the last quarter. Finally, Nordea Investment Management AB increased its stake in shares of ACADIA Pharmaceuticals by 1.3% in the fourth quarter. Nordea Investment Management AB now owns 264,031 shares of the biopharmaceutical company’s stock worth $4,952,000 after buying an additional 3,516 shares during the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Mark C. Schneyer sold 2,708 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Tuesday, April 8th. The shares were sold at an average price of $14.82, for a total transaction of $40,132.56. Following the sale, the executive vice president now owns 59,456 shares in the company, valued at $881,137.92. This trade represents a 4.36 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total transaction of $89,673.37. Following the completion of the transaction, the director now owns 17,595 shares of the company’s stock, valued at $320,756.85. This trade represents a 21.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 14,169 shares of company stock valued at $242,686. Corporate insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.